Recombinant Biotinylated Human ACE2 / ACEH Protein, His,Avitag™, 25µg

Background
Angiotensin-converting enzyme 2 (ACE2) is also known as ACEH (ACE homolog), is an integral membrane protein with considerable homologous to ACE, which belongs to the peptidase M2 family. ACE2 is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin 1-7. ACE2 may be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, ACE-2 serve as functional receptor for the spike glycoprotein of both coronaviruses. ACE2 is activated by chloride and fluoride, but not bromide and Inhibited by MLN-4760, cFP_Leu, and EDTA, but not by the ACE inhibitors linosipril, captopril and enalaprilat. ACE2 is active from pH 6 to 9, and the optimum pH is 6.5 in the presence of 1 M NaCl.

Source
Recombinant Biotinylated Human ACE2, His,Avitag (AC2-H82E6) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Ser 740 (Accession # Q9BYF1-1).
Predicted N-terminus: Gln 18

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 87.2 kDa. The protein migrates as 95-125 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Bottom-up Assembled Synthetic SARS-CoV-2 Miniviruses Reveal Lipid Membrane Affinity of Omicron Variant Spike Glycoprotein"
Yagüe Relimpio, Fink, Bui et al
ACS Nano (2023)
(2) "A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion"
Feng, Yang, Yang et al
Mol Ther (2023)
(3) "Angiotensin-converting enzyme - human amniotic mesenchymal stem cells improve pulmonary vascular remodeling in rats with pulmonary hypertension by promoting angiogenesis and counteracting inflammation"
Wu, Liu, Ba et al
Int J Clin Exp Pathol (2023) 16 (10), 282-293
Showing 1-3 of 12821 papers.

Citations

(1) "Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity"
Authors: Pratik Adhikary, Sashi Kandel, et al.
Journal: Advanced Therapeutics. 2021
Application: ELISA
(2) "Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2"
Authors: Dong J, Huang B, Wang B, et al.
Journal: Scientific reports 2021
Application: ELISA
(3) "Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients"
Authors: Tang J, Ravichandran S, Lee Y, et al.
Journal: Nature communications 2021
Application: ELISA
(4) "High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme"
Authors: Esparza, Thomas J et al.
Journal: Scientific reports 2020
Application: Binding Assay
(5) "Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. BioRxiv preprint. doi: https://doi.org/10.1101/2020.06.17.157982"
Authors: Tyler N Starr, Allison J Greaney , Sarah K Hilton, et al.
Journal: BioRxiv 2020
Application: Flow cytometry